Friday | September 9th 2022

CEO MESSAGE

On behalf of the entire team at LSBC, I hope you all enjoyed a restful long weekend leading into a busy fall. As calendars start to fill up, here are some industry events that may be of interest, including a free webinar, Gairdner’s Global Perspective Panel Series, on where we stand more than two years since the pandemic began. The panel, presented by Telus Health, is on September 13th and you can register here. Genome BC also invites you to join Dr. Carolyn Hogg on September 15th for a special in-person event entitled “Biodiversity Conservation in the Age of Extinction”. The event will be held at the Vancouver Convention Centre West, and is free but online registration is required. Finally, the 22nd Annual Healthcare Summit: The Future of Innovation, Personalized Medicine and Genomics, is coming up on September 22nd and 23rd. Register here to attend.

 

Applications are also still open to present at LSBC’s 7th Annual 2022 Invest in BC presented by Lumira Ventures. We encourage all interested companies within our life sciences community in the digital health, medtech, diagnostics and biotechnology sectors to apply to pitch by September 14.

 

Industry and Member News

 

Exciting news from Evonik and Shell, who recently announced a commitment to reduce heavy duty transport CO2e emissions with Bio-LNG from Shell. And, a team of UBC researchers working on developing oral insulin tablets as a replacement for daily insulin injections have made a recent, game-changing discovery, allowing it to be absorbed by rats in the same way as injected insulin.

 

Last week, we highlighted the Government of B.C.’s new funding for Mitacs, with an $8.6 million one-time provincial investment to connect student researchers with innovative companies and help students thrive within our sector. On that note, at LSBC, we were also pleased to welcome four new co-op students to our team for the fall term. These opportunities are made possible by BioTalent Canada’s Student Work placement program. Join us in welcoming Boshra Moheq, Cameron Razempour, Marko Juvan, and Patrick Deane!

 

We’d also like to extend a warm welcome to new LSBC members: The Canadian Alliance for Skills and Training in Life Sciences, Incyte Biosciences Canada, and The GelMA Company. Congratulations also to The GelMA Company for its announcement around securing a $510,000 contract with the Government of Canada.  

 

Kudos

 

Congratulations to UVic and Vancouver Island Life Sciences who celebrated the opening of a new community-based innovation hub called the BioInnovation Hub, aimed to help advance health and life sciences innovation. We are also pleased to see the fruition of more diversity efforts within our sector. The Deloitte Health Equity Institute has donated $150,000 to The Leverage Network to help advance Black leadership in healthcare C-suite and governance roles. New Ventures BC announced the Top 11 companies of this year’s startup competition. Congratulations to the organizations, including some of our members, that made the list!

 

In closing, a reminder that our annual AGM is coming up on September 15th, and is open to members and sponsors. Register online to join us virtually or in-person at the Fasken Vancouver Office for a continental breakfast reception before the event begins. We also look forward to celebrating with so many of you on September 22nd at our 24th Annual Life Sciences BC Awards presented by Farris. Tickets are waitlisted, but we’re pleased to offer an Awards Networking and Viewing Reception for the first time! To RSVP for the reception or to join our gala waitlist, register online.

 

Have a great weekend,

 

Wendy and the LSBC team



PLATINUM SPONSORS

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business 

InMed Pharmaceuticals Inc., a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced an update on its research/development and commercial activities. Eric A. Adams, InMed CEO, states, “The Company continues to execute on its research and development (“R&D”) plans to complete enrollment in a Phase 2 clinical program in epidermolysis bullosa (“EB”)…READ MORE

NervGen Pharma Presenting at Upcoming Military Health System Research Symposium and The 61st International Spinal Cord Society Annual Scientific Meeting

NervGen Pharma Corp., a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will present a poster at the upcoming Military Health System Research Symposium on September 12-15, 2022 and will also present an oral presentation at the 61st International Spinal Cord Society Annual Scientific Meeting on September 17, 2022...READ MORE

FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants via Immunization of Pregnant Women

Pfizer Inc. announced that its investigational Group B Streptococcus vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy...READ MORE

Ondine Reports Successful US Phase 2 Trial Data

Ondine Biomedical Inc. announces that its Phase 2 BENEFIT-APDT clinical trial has met the primary endpoint of bacterial load reduction after nasal photodisinfection. Results from the study showed that nasal photodisinfection eliminated or significantly decreased S. aureus in 92% of carriers (P<0.001) immediately after treatment. There were no reportable adverse events or unexpected safety issues; treatment was found to be safe and well tolerated...READ MORE

Late-Breaking Dupixent® (Dupilumab) Data at Ers 2022 Show Consistent Efficacy and Safety Profile for up to Two Years in Children Aged 6 to 11 Years With Moderate-to-Severe Asthma 

Results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation. These results were presented in a late-breaking session at the 2022 European Respiratory Society International Congress, which coincides with the milestone that more than 500,000 people around the world have been treated with Dupixent in its approved indications...READ MORE

The GelMA Company Wins $510,000 Contract with the Government of Canada 

The GelMA Company, a biotechnology start-up that produces high-quality biomaterials using a patented process, is excited to announce that it has secured a $510,000 contract with its new customer and strategic partner, the Government of Canada. This contract also makes The GelMA Company eligible for Direct Buy contracts with any Government of Canada organization for a period of 3 years. Each contract has a potential value of up to $8 million dollars...READ MORE

INDUSTRY NEWS

TELUS Completes Acquisition of LifeWorks

TELUS Corporation has announced the completion of the previously disclosed $2.3 billion acquisition of LifeWorks Inc., a world leader in providing digital and in-person solutions that support the total wellbeing of individuals – mental, physical, financial and social. TELUS Health is now positioned to support corporate clients across more than 160 countries and covering more than 50 million lives and growing worldwide...READ MORE

GOLD SPONSORS

EHSS Officer



Evonik’s Vancouver business operations is a development partner to the world’s pharmaceutical companies for parenteral lipid nanoparticle drug products. As an enabling contract development manufacturing organization (CDMO) partner, we offer drug formulation design, process development, scale-up, and clinical production.


The incumbent is responsible for the oversight of Environmental Health, Safety and Security (EHSS) programs and strategically managing the transition towards EHSS excellence at the site.









LEARN MORE

Manager, Intellectual Property



Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, initially focused on the treatment of cancer. 


Zymeworks is seeking a highly motivated professional to join their Intellectual Property (IP) team as a Manager or Senior Manager of IP. This is an excellent opportunity for those looking to take their career to the next level, reporting directly to the Senior Director, Intellectual Property who is located at their headquarters in Vancouver, BC. This position can either be based in offices in Vancouver (BC) or Remote (CA).




LEARN MORE

Technical Project Manager, CMC


NervGen is seeking a highly motivated and qualified individual for the position of Technical Project Manager, Chemistry, Manufacturing and Controls (CMC). This role reports to the Director, Pharmaceutical Development and will be responsible in coordinating and participating in the management of CMC activities. Focus will be on drug substance (DS) with active participation in drug product (DP) and clinical supplies activities. As an integral member of the development team, the Technical Project Manager actively contributes to CMC strategic planning and deliverables.








LEARN MORE

SILVER SPONSORS
New Member Welcome

GuideStar Medical Devices lead product, EpiZact, aims to make the epidural procedure dramatically safer for patients. When using EpiZact, the forward progress of the needle is automatically stopped once the epidural space is reached, positioning the needle tip exactly in the right place. EpiZact is the first device that automatically stops the needle, and aims to add a margin of safety that has never existed before.



Visit Website

Member Spotlight

Our Global Life Sciences Sector brings together a worldwide network of 23,000 sector-focused professionals to anticipate trends, identify their implications and help our clients create competitive advantage. We can help you navigate your way forward and achieve sustainable success in the new health-outcomes-driven ecosystem.




Visit Website

BRONZE SPONSORS
Post a Job on the LSBC Website!
LSBC Membership Discounts on Job Postings
 
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's The Petri Dish. After your first five posts, you will also receive 25% off all job postings on The Petri Dish. Want more info? Contact talent@lifesciencesbc.ca
Facebook  Twitter  Linkedin  Instagram